A federal appeals court on Thursday ordered a new trial in a high-profile patent infringement dispute over Sanofi’s drug Praluent and lifted a permanent injunctionbarring sales of the biologic, used to fight high cholesterol.
Judge Sharon Prost of the U.S. Court of Appeals for the Federal Circuit found that a Delaware federal judge improperly excluded evidence from Sanofi and its development partner Regeneron Pharmaceuticals Inc. in the case and relayed incorrect instructions to a jury, which last year upheld the validity of Amgen Inc.’s patents on a competing biologic, Repatha.
